PDCD1 and cutaneous melanoma: We further conducted correlational analysis for the signature and the expression of tumor immune checkpoint genes and noticed that with the risk score was significant with the expression of the checkpoint markers, such as PD-1, PD-L1, and CTLA-4, implicating the potential roles of the signature in the response to immunotherapy in cutaneous melanoma patients.